Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the ...
Trastuzumab deruxtecan (T-DXd) was effective in patients with HER2-positive (HER2+) metastatic breast cancer, with no new ...
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...
Nashville, TN, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BACK) (“IMAC Holdings” or the “Company”), a leader in innovative ...
Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.
A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach ...
The DESTINY-Breast12 trial revealed that trastuzumab deruxtecan (T-DXd) effectively targets brain metastases in HER2-positive ...
The findings, from an international clinical trial, reinforce earlier findings of the benefits of the drug -- trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate -- in these patients ...
A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach ...
Medpage Today on MSN7d
Another Win for Antibody-Drug Conjugate in HER2+ Breast Cancer With Brain MetsPFS came in at 61.6% overall, at 62.9% in those with stable brain metastases, and at 59.6% in those with active brain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback